Increased invasion and tumorigenicity capacity of CD44+/CD24- breast cancer MCF7 cells in vitro and in nude mice

Cancer Cell International

Tiejun Wang¹  Hongmei Zhang²  Yueliang Yao¹  Yubing Chen¹  Wenxing Yan¹ 

[1] Department of Radiotherapy, Second Affiliated Hospital of Jilin University, 130021, Changchun, China;China-Japan Union Hospital of Jilin University, Changchun, China

关键词: Invasive ability;    Tumorigenicity;    Ultrastructure;    Breast cancer stem cells;   

Others  :  793561
DOI  :  10.1186/1475-2867-13-62

 received in 2013-02-06, accepted in 2013-06-05,  发布年份 2013

【 摘 要 】

Background

Identification of cancer stem cells (CSCs) and their behaviors will provide insightful information for the future control of human cancers. This study investigated CD44 and CD24 cell surface markers as breast cancer CSC markers in vitro and in vivo.

Methods

Flow cytometry with CD44 and CD24 markers was used to sort breast cancer MCF7 cells for scanning electron microscopy (SEM), tumor cell invasion assay, and nude mouse xenograft assay.

Results

Flow cytometry assay using CD44 and CD24 markers sorted MCF7 cells into four subsets, i.e., CD44⁺/CD24^-/low, CD44^-/CD24⁺, CD44⁺/CD24⁺, and CD44^-/CD24^-. The SEM data showed that there were many protrusions on the surface of CD44⁺/CD24^-/low cells. CD44⁺/CD24^-/low cells had many microvilli and pseudopodia. The CD44⁺/CD24^-/low cells had a higher migration and invasion abilities than that of the other three subsets of the cells. The in vivo tumor formation assay revealed that CD44⁺/CD24^- cells had the highest tumorigenic capacity compared to the other three subsets.

Conclusion

CD44 and CD24 could be useful markers for identification of breast CSCs because CD44⁺/CD24^-/low cells had unique surface ultrastructures and the highest tumorigenicity and invasive abilities.

【 授权许可】

   
2013 Yan et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Al-Hajj M, Becker MW, Wicha M, Weissman I, Clarke MF: Therapeutic implications of cancer stem cells. Curr Opin Genet Dev 2004, 14:43-47.
• [2]Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003, 100:3983-3988.
• [3]Charafe-Jauffret E, Ginestier C, Iovino F, Wicinski J, Cervera N, Finetti P, Hur MH, Diebel ME, Monville F, Dutcher J, Brown M, Viens P, Xerri L, Bertucci F, Stassi G, Dontu G, Birnbaum D, Wicha MS: Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res 2009, 69:1302-1313.
• [4]Li F, Tiede B, Kang Y, Massagué J: Beyond tumorigenesis: cancer stem cells in metastasis. Cell Res 2007, 17:3-14.
• [5]Velasco-Velázquez MA, Popov VM, Lisanti MP, Pestell RG: The role of breast cancer stem cells in metastasis and therapeutic implications. Am J Pathol 2011, 179:2-11.
• [6]Dean M, Fojo T, Bates S: Tumour stem cells and drug resistance. Nat Rev Cancer 2005, 5:275-284.
• [7]Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, Dirks PB: Identification of a cancer stem cell in human brain tumors. Cancer Res 2003, 63:5821-5828.
• [8]O'Brien CA, Pollett A, Gallinger S, Dick JE: A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007, 445:106-110.
• [9]Zhang S, Balch C, Chan MW, Lai HC, Matei D, Schilder JM, Yan PS, Huang TH, Nephew KP: Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res 2008, 68:4311-4320.
• [10]Tsuchiya S, Li F: Electron microscopic findings for diagnosis of breast lesions. Med Mol Morphol 2005, 38:216-224.
• [11]Zhao YD, Huang Q, Zhang TY, Dong J, Wang AD, Ding F, Lan Q, Gu XS, Qin ZH: [Ultrastructural analysis of glioma stem cells-progenitors]. Zhonghua Zhong Liu Za Zhi 2008, 30:663-667.
• [12]Paniz Mondolfi AE, Slova D, Fan W, Attiyeh FF, Afthinos J, Reidy J, Pang Y, Theise ND: Mixed adenoneuroendocrine carcinoma (MANEC) of the gallbladder: a possible stem cell tumor? Pathol Int 2011, 61:608-614.
• [13]Pham PV, Phan NL, Nguyen NT, Truong NH, Duong TT, Le DV, Truong KD, Phan NK: Differentiation of breast cancer stem cells by knockdown of CD44: promising differentiation therapy. J Transl Med 2011, 9:209. BioMed Central Full Text
• [14]Zielske SP, Spalding AC, Wicha MS, Lawrence TS: Ablation of breast cancer stem cells with radiation. Transl Oncol 2011, 4:227-233.
• [15]Shipitsin M, Campbell LL, Argani P, Weremowicz S, Bloushtain-Qimron N, Yao J, Nikolskaya T, Serebryiskaya T, Beroukhim R, Hu M, Halushka MK, Sukumar S, Parker LM, Anderson KS, Harris LN, Garber JE, Richardson AL, Schnitt SJ, Nikolsky Y, Gelman RS, Polyak K: Molecular definition of breast tumor heterogeneity. Cancer Cell 2007, 11:259-273.
• [16]Abraham BK, Fritz P, McClellan M, Hauptvogel P, Athelogou M, Brauch H: Prevalence of CD44+/CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. Clin Cancer Res 2005, 11:1154-1159.
• [17]Wicha MS: Cancer stem cell heterogeneity in hereditary breast cancer. Breast Cancer Res 2008, 10:105. BioMed Central Full Text
• [18]Park SY, Lee HE, Li H, Shipitsin M, Gelman R, Polyak K: Heterogeneity for stem cell-related markers according to tumor subtype and histologic stage in breast cancer. Clin Cancer Res 2010, 16:876-887.
• [19]Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S, Schott A, Hayes D, Birnbaum D, Wicha MS, Dontu G: ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007, 1:555-567.
• [20]Smith GH, Chepko G: Mammary epithelial stem cells. Microsc Res Tech 2001, 52:190-203.
• [21]Chepko G, Dickson RB: Ultrastructure of the putative stem cell niche in rat mammary epithelium. Tissue Cell 2003, 35:83-93.
• [22]Pierce GB, Nakane PK, Martinez-Hernandez A, Ward JM: Ultrastructural comparison of differentiation of stem cells of murine adenocarcinomas of colon and breast with their normal counterparts. J Natl Cancer Inst 1977, 58:1329-1345.
• [23]Black PH: Shedding from the cell surface of normal and cancer cells. Adv Cancer Res 1980, 32:75-199.
• [24]Nicolson GL, Poste G: The cancer cell: dynamic aspects and modifications in cell-surface organization (first of two parts). N Engl J Med 1976, 295:197-203.
• [25]Spring FA, Dalchau R, Daniels GL, Mallinson G, Judson PA, Parsons SF, Fabre JW, Anstee DJ: The Ina and Inb blood group antigens are located on a glycoprotein of 80,000 MW (the CDw44 glycoprotein) whose expression is influenced by the In(Lu) gene. Immunology 1988, 64:37-43.
• [26]Sillanpää S, Anttila MA, Voutilainen K, Tammi RH, Tammi MI, Saarikoski SV, Kosma VM: CD44 expression indicates favorable prognosis in epithelial ovarian cancer. Clin Cancer Res 2003, 9:5318-5324.
• [27]Li D, Zheng L, Jin L, Zhou Y, Li H, Fu J, Shi M, Du P, Wang L, Wu H, Chen GY, Zheng P, Liu Y, Wang FS, Wang S: CD24 polymorphisms affect risk and progression of chronic hepatitis B virus infection. Hepatology 2009, 50:735-742.
• [28]Nestl A, Von Stein OD, Zatloukal K, Thies WG, Herrlich P, Hofmann M, Sleeman JP: Gene expression patterns associated with the metastatic phenotype in rodent and human tumors. Cancer Res 2001, 61:1569-1577.
• [29]Aigner S, Ruppert M, Hubbe M, Sammar M, Sthoeger Z, Butcher EC, Vestweber D, Altevogt P: Heat stable antigen (mouse CD24) supports myeloid cell binding to endothelial and platelet P-selectin. Int Immunol 1995, 7:1557-1565.
• [30]Magee JA, Piskounova E, Morrison SJ: Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell 2012, 21:283-296.